Loss for 10 years, but turned the loss into profit with "one shot"

July 21, 2021

Over the weekend, Cansino announced the performance forecast for the first half of 2021. During the period, it is expected to realize operating income of 2-2 billion yuan (49532.59%-54495.85%); net profit attributable to owners of the parent company will be 9-10.5 billion yuan, deducting non-net With a profit of 850 million to 1 billion yuan, it successfully turned losses into profits. It is reported that CanSino was established in Tianjin on January 13, 2009, and is committed to the research and development, production and commercialization of innovative vaccines for public health in China and the world. After nearly 10 years of research and development, 16 vaccines covering 13 infectious diseases have been established. The R&D pipeline was listed on the Hong Kong Main Board in 2019, and officially listed on the Shanghai Stock Exchange Science and Technology Innovation Board the following year. It was also this year that the new crown vaccine jointly developed with the Institute of Bioengineering of the Academy of Military Medicine of the Academy of Military Sciences was approved for emergency use in the military system. On February 25, 2021, Cansino vaccine received conditional approval for registration from the China Food and Drug Administration, becoming the first domestically-made adenovirus vector new coronavirus vaccine approved. Up to now, Cansino vaccine has been approved for marketing in many places except China, Mexico, Pakistan and other places.

The performance soars, the new crown vaccine makes great contributions

Regarding the soaring semi-annual performance, Cansino also said that the major change in the company's performance in the first half of the year was the increase in revenue due to the approval of the new crown vaccine in many places.

According to statistics, this performance has turned from a loss to a profit, which is the only time when CanSino has a positive revenue since its establishment. 2021 may also be CanSino's cross-history year.

At the same time, in addition to the new crown vaccine, Cansino has also completed the new drug registration for the Ebola virus disease vaccine. Two meningococcal vaccine products have also been submitted and accepted by the NDA. The DPT vaccine, pneumonia conjugate vaccine, and tuberculosis vaccine are in clinical practice. The experimental stage. The research and development of 16 innovative vaccine products with 13 indications on the multi-project end is also steadily proceeding.

Under similar comparisons, CanSino's new crown sales are not the best

According to the current published data, compared with the four major vaccinations commonly vaccinated by Chinese people, Cansino's vaccine performance in the first half of the year is not top-notch, whether it is in the domestic or international markets. On the one hand, according to a press conference on the economic operation of central enterprises in the first half of the year held by the State Council Information Office of Sinopharm Group on July 16, Sinopharm’s new crown inactivated vaccine has been certified for emergency use by the World Health Organization and has now supplied a total of 620 million doses; The growth of pharmaceutical revenue reflects the sales of Coxing Zhongwei's new crowns and the exposure of the number of Zhifei biological inoculations. It is speculated that the sales of the above-mentioned three new crown vaccines are expected to exceed Cansino. And recently, the new coronavirus inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group was approved for emergency use in people aged 3-17, further expanding the target population of vaccination. And this part of the vacancy layout is 17.95% of China's total population. Based on the vaccination demand of 2 doses per person, the average price of 100 yuan per dose is estimated, which is also a new market of nearly 45 billion.

to sum up

All in all, as the first company to announce half-year results for the new crown vaccine, Cansino has indeed become a good opportunity for Cansino to prove itself. At the same time, several subsequent new crown vaccine manufacturers will continue to bring us more What a surprise. There is no doubt that the keyword in 2020 may be "new crown epidemic", but the keyword in 2021 will definitely have a place for "new crown vaccine".

Entre em contato conosco

Author:

Ms. Yi

E-mail:

info@hychem-china.com

Phone/WhatsApp:

+8618888297294